Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twelve patients with advanced malignant disease were entered onto a Phase I study of escalating doses of beta-interferon serine given by 4-h i.v. infusion twice a wk. Three patients each were entered at starting doses of 0.01, 1, 10, and 30 million units (MU)/m2. Doses escalation within individual patients was allowed to a maximum dose of 400 MU/m2. Fever, chills, fatigue, and acral cyanosis were commonly seen and increased in frequency at higher doses. Myalgia, nausea, diarrhea, headache, and confusion were seen at lesser frequencies. Mild leukopenia, paresthesia, infusion site erythema, and hypotension were each seen in one patient. No conventional maximal tolerated dose could be defined, since several patients underwent escalation to the highest allowable dose and seemed to develop tolerance to acute toxicities. However, a maximal starting dose of 10 MU/m2 was identified, such that those begun at this level or below tolerated semiweekly dose escalation, while those begun at 30 MU/m2 could not tolerate continued therapy. Detectable serum interferon levels were noted during treatment at 10 and 30 MU/m2, the levels at which significant toxicity also first appeared. A maximal starting dose of 10 MU/m2, with gradual escalation as tolerance to side effects develops, is suggested if therapy with high-dose beta-interferon serine is given by 4-h infusion.
 ...
PMID:Phase I study of recombinant beta-interferon given by four-hour infusion. 380 98

Negative pi-meson (pion) therapy employing dynamic scanning with a focused spot of convergent beams has been in use since 1981 at SIN. Three-dimensional conformation of the treatment volume to the target volume can thus be achieved. Following previously reported Phase I and Ib clinical trials, a Phase II trial was initiated with the goal of treating primary deep-seated tumors in a dose optimization schedule which included stepwise increase of total pion dose and of target volume. Patients with multicentric superficial bladder tumors who were cystectomy candidates were initially selected. Since then, more invasive cases have been treated. A graded scoring of acute tissue reactions was employed. Follow-up periods were from 10 to 20 months. The pion dose escalation ranged from 3000 rad (minimum) to 3600 rad (minimum) in 20 fractions over 5 weeks. The treatment volumes encompassed 190 cc for local to 1,820 cc for extended volume therapy. Treatment reactions ranged from a faint erythema and increase of bladder frequency to dry desquamation, mild nausea, moderate dysuria, and moderate proctitis or diarrhea with mucus. These reactions were closely related to treatment volume and site. One severe late cystitis has occurred in a patient treated with 2 courses of pions (4475 rad). Mild to moderate late proctitis has been seen in 4 patients. Ten of 13 bladder cancer patients had local control of disease while all 3 pancreas or biliary tract cancer patients had microscopic residual disease locally at time of death from metastasis. A total of 11 of 17 patients are thus clinically or pathologically free of local tumor to time of last observation.
 ...
PMID:The Piotron: II. Methods and initial results of dynamic pion therapy in phase II studies. 391 63

Intravenous infusion of prostaglandins (PG) for pregnancy termination has been associated with long duration of infusion and side effects (nausea, vomiting, diarrhea, and erythema at the site of injection). Some of these side effects have been eliminated through the use of intravaginal and intrauterine administration of PGs. The authors studied the effects of intraamniotic administration of PG on the 2nd trimester pregnant uterus based on the observations that PGE2 and F2alpha are found in samples of amniotic fluid obtained during spontaneous abortion. Single intraamniotic administration of 2.5-5.0 mg PGE2 or 25 mg PGF2alpha in 10 women 13-22 weeks pregnant stimulated uterine contraction and resulted in abortion in every case. 8 women had complete abortion and 2 necessitated manual removal of the placenta. Injection-abortion interval ranged from 4-1/2-18 hours, with a mean of 11.4 hours. 4 women experienced nausea and 3 had vomiting. There were no other side effects. This route of administration appears to produce a local action on the uterus, and the procedure does not require withdrawal of any amniotic fluid.
 ...
PMID:Second trimester abortion with single intra-amniotic injection of prostaglandins E2 or F2 alpha. 410 91

A 42-yr-old white woman reported onset in 1976 of local pruritus, burning, erythema, and edema within minutes after exposure in heat. With more extensive exposure, she occasionally had transient headaches and nausea. In order to investigate the etiology of this condition, her forearm was exposed to water at 44 degree C for 4 min. Within a few minutes, a lesion identical to her spontaneously induced ones developed only at the area exposed to heat. Samples of venous blood from this extremity demonstrated a transient rise in plasma histamine levels without any significant change in serum hemolytic complement activity or in C3, C4, or factor B. These findings suggest that this rare syndrome involves local activation of mediator release from mast cells, without participation of the complement system.
 ...
PMID:Local heat urticaria/angioedema: evidence for histamine release without complement activation. 616 Nov 44

139 patients with vitiligo of long duration were treated with oral 8-MOP and UVA. 22 patients had focal and 117 generalized vitiligo. 27 had vitiligo on the skin of their face and/or neck and 58 on their hands and/or feet. Vitiligo of the face and/or neck responded very well to the treatment, 14 of 27 (52%) repigmenting completely, while the treatment results of hands and/or feet were poor (complete repigmentation in 2 of 58 cases (3%). In cases with focal vitiligo total repigmentation was observed much more frequently (in 11 of 22 cases) than in cases with generalized vitiligo (in 23 of 117 cases). Acute toxic effects were frequent, erythema in 55 cases (40%), nausea in 46 cases (33%), pruritus in 16 cases (12%) and headache in 8 cases (6%). Long-term adverse effects such as hypertrichosis and actinic keratoses occurred in 3 cases each. 6 patients (4%) had elevated transminases at some stage of the treatment. This did not cause withdrawal from treatment in any of the cases.
 ...
PMID:Treatment of vitiligo with oral methoxsalen and UVA. 653 Dec 91

Further work on the treatment of postoperative pain with non-narcotic analgesics involving an investigation of the effect of twice the customary dose of lysine acetylsalicylate in a double-blind trial versus meperidine is reported. In addition to subjective and objective pain, the parameters included blood pressure, pulse rate, breathing rate, sweating, pupil diameter, nausea, vomiting, somnolence, hiccuping feeling of cold, erythema, dizziness, and nasograstric sound intolerance. Application of Wilcoxon's non-parametric tests and the chi-square test showed that the drug was as good as or better than meperidine with regard to pain, and performed very well overall with respect to the other parameters. The conclusion is drawn that its administration in high doses is justified in many patients subjected to general surgery.
 ...
PMID:[Treatment of postoperative pain with non-narcotic drugs; evaluation of lysine acetylsalicylate in high doses. Double-blind controlled study]. 679 21

A double-blind study was designed to test the hypothesis that local side-effects during i. v. administration of erythromycin lactobionate depend on the drug concentration and that they can therefore be minimized by dissolving erythromycin in a larger infusion volume. Forty healthy students were assigned in a randomized sequence to four 30 min infusions: 120 and 250 ml of erythromycin lactobionate (1 g in 0.9% NaCl) and 120 and 250 ml of placebo (0.9% NaCl). An unexpectedly high incidence (95% and 80% for the infusion volumes of 120 and 250 ml, respectively) of severe systemic side-effects was observed during the first 79 infusions. Because all of these systemic side-effects were associated with the infusion of erythromycin, the study was terminated at this point. Side-effects included abdominal cramps, nausea, vomiting, dizziness and profuse sweating. The postulated positive effect of lower erythromycin concentrations in the infusion on local side-effects (pain at the infusion site, erythema) was marginal (63% vs. 45%). Compared to the systemic side-effects, the problem of local tolerance is less important. In young adults, 30 min infusions of 1 g erythromycin lactobionate are associated with a high incidence of systemic side-effects which may be due to an age-dependent effect of the drug on smooth muscle.
 ...
PMID:Side-effects due to the intravenous infusion of erythromycin lactobionate. 688 76

The effectiveness of methoxsalen and ultraviolet light (PUVA) in treating is reviewed. The use of this therapy, its mechanism of action, pharmacology, pharmacokinetics, adverse reactions, dosage, and comparison with other forms of therapy, are discussed. Administered orally, methoxsalen in combination with long-range ultraviolet light (UVA) is effective in treating patients with moderate to severe forms of psoriasis. Although the short-term risks associated with PUVA therapy are minimal, the long-term risks of oncogenicity have not been evaluated thoroughly. Common adverse reactions to methoxsalen and UVA are nausea, pruritus, and erythema, but usually they can be managed by minor modifications in the treatment regimen. Methoxsalen and UVA therapy should be reserved for patients with moderate to severe forms of psoriasis that do not respond to other forms of therapy until the long-term risks of oncogenicity are evaluated.
 ...
PMID:Photochemotherapy of psoriasis with methoxsalen and longwave ultraviolet light (PUVA). 702 Apr 14

1 Fifty infusions of epoprostenol (PGI2) were made, usually increasing the infusion rate until adverse effects were encountered. The volunteers were appraised that they might experience headache and facial flushing. 2 Facial flushing, headache, tachycardia and decrease in diastolic blood pressure were seen in almost all subjects. Erythema over the venous infusing site was also encountered in 13 infusions. Less common effects were sudden bradycardia, pallor and sweating--the vagal reflex--(seven times) and chest pain (twice). Other complaints included restlessness, abdominal discomfort, nausea and drowsiness. 3 The literature on side effects reported during PGI2 infusion is reviewed and recommendations are made concerning administration of PGI2.
 ...
PMID:Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man. 704 12

In this retrospective study, we reviewed the patterns of use of the Edmonton Injector (EI) in 100 consecutive cancer patients. Seventy-eight patients used the EI for an average of 23 +/- 27 days. The main reasons for starting the EI were nausea (37 patients) and severe pain (31 patients). The median opioid dose equivalent to parenteral morphine (MEDD) was 264 +/- 443 mg/day. The mean duration of the subcutaneous injection site was 6.5 +/- 9.2 days. The most frequent reasons for change were accidental needle pulling (59%) and erythema (12%). Only two patients developed local infection (1% of 196 sites). The average cost of treatment was $1.65 Canadian per patient per day. No mechanical problems or refusals to start or continue treatment were detected. We conclude that the EI is a safe and simple device that allows for cost-effective parenteral administration of opioids for cancer pain.
 ...
PMID:Use of the Edmonton Injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. 752 82


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>